These non-significant results might be due to the limited number of doses of trastuzumab administered, as DCIS admixed with HER2-positive IBC often shows substantial regression after neoadjuvant treatment [44]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.